Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancerBOTHELL, Wash ...
A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.
Peptide-based signaling systems occupy a central position in modern biochemical inquiry due to their potential to interface ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Metastatic breast cancer (mBC) remains an incurable disease, and most patients will experience disease progression during their treatment course. Although endocrine therapy remains the mainstay of ...
Membrane-initiated estrogen receptor α (mERα) in specific cell types found crucial for bone strength
Researchers found that mice lacking membrane ERα signaling in osteoblast lineage cells had significantly lower cortical bone mass, highlighting the pathway’s critical role in maintaining the strength ...
Estrogen-dependent cancers are cancers that grow in response to the hormone estrogen. These include certain types of breast cancer, uterine cancer, and ovarian cancer. In these cancers, estrogen can ...
Use of an unapproved triple-hormone receptor agonist bought online led to extreme side effects stemming from intractable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results